Skip to content

Effects of remazolam vs etomidate on haemodynamics and adverse events during the induction of general anaesthesia in elderly patients - A randomised, controlled, non-inferiority study

Effects of remazolam vs etomidate on haemodynamics and adverse events during the induction of general anaesthesia in elderly patients - A randomised, controlled, non-inferiority study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124111
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-05-27
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group R : Remazolam:Patients randomised to group R were given remazolam 0.25mg/kg for induction of anaesthesia
Group E : Etomidate:Patients randomised to group E were given etomidate 0.2mg/kg for induction of anaesthesia.

Sponsors

Beijing Tsinghua Changgung Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 65 years 2. Intended elective surgery under combined intravenous-inhalation anesthesia 3. Intended use of a single-lumen endotracheal tube 4. Voluntary participation with signed informed consent

Exclusion criteria

Exclusion criteria: 1. Cognitive dysfunction or neuropsychiatric disorders. 2. Patients with confirmed or suspected abuse of, or long-term use of, narcotic sedatives/analgesics, hypnotics, or antidepressants. 3. Patients with contraindications or hypersensitivity/allergy to the study drugs, including benzodiazepines, etomidate, rocuronium, or any of their components. 4. Anticipated to have a difficult airway. 5. Expected to require postoperative transfer to the ICU. 6. History of adrenocortical insufficiency, porphyria, or chronic corticosteroid therapy. 7. Severe arrhythmias, including severe sinus bradycardia (heart rate [HR] = 180 mmHg and/or diastolic blood pressure [DBP] >= 110 mmHg). 9. Abnormal hepatic or renal function (Child–Pugh class B or C; blood urea nitrogen > 1.5 times the upper limit of the normal reference range and/or serum creatinine above the upper limit of the normal reference range). 10. Other patients deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
The maximum change in mean arterial pressure;Time of loss of consciousness;

Secondary

MeasureTime frame
Change in MAP relative to baseline within 5 minutes after tracheal intubation;Heart rate fluctuations during induction of anaesthesia;Occurrence of adverse drug reactions during induction of anaesthesia;

Countries

China

Contacts

Public ContactZhang Huan

Beijing Tsinghua Changgung Hospital

zhanghuan00558@163.com+86 10 5611 8349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026